20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States

BACKGROUND: Individuals who are immunocompromised (IC) due to disease or therapy are at increased risk of herpes zoster (HZ), with HZ cases in IC populations also resulting in increased health care resource use and costs as compared with the immunocompetent population. This study assesses the cost-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Curran, Desmond, Salem, Ahmed, Lorenc, Stéphane, Patterson, Brandon, Carrico, Justin, Hicks, Katherine A, La, Elizabeth M, Poston, Sara, Carpenter, Christopher F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644296/
http://dx.doi.org/10.1093/ofid/ofab466.222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644296/
http://dx.doi.org/10.1093/ofid/ofab466.222

Ejemplares similares